Full-Time

Cell Therapy Account Manager

Posted on 4/16/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical company developing innovative medicines

No salary listed

Senior

Company Historically Provides H1B Sponsorship

Sydney NSW, Australia

The role covers the South West / ACT territory.

Category
Customer Success
Strategic Account Management
Sales & Account Management
Biology & Biotech
Required Skills
Sales
Marketing
Requirements
  • Minimum 5 years Haematology sales experience
  • Demonstrated ability and desire to provide unprecedented customer support across stakeholder groups
  • Demonstrate initiative and a willingness to work hands-on and with a sense of urgency, in a fast-paced environment
  • Demonstrated ability to be a contributing member of a high performing team where individual and team success align
  • Experience executing with products/therapies that require complex customer delivery including logistics management
  • Ability to successfully work and collaborate with field based and internal cross functional partners
  • Strong business acumen and ability to evaluate and apply data to inform decision making
  • Outstanding written, verbal and presentation skills with internal and external stakeholders
  • Possesses a long term, strategic understanding of the Haematology/Oncology & SCT market in Australia
  • Launch experience within academic hospitals is a must
  • Experience with managing large accounts including strategic planning, problem solving and execution
  • Working knowledge of regulatory and compliance and ability to work daily with SOPs
  • Exceptional organisational and time management skills
  • Exceptional interpersonal and influencing skills
  • Strong written and verbal communication skills
  • Ability to build consensus across multiple cross-functional teams
  • Proven ability to successfully communicate and execute organisational goals and brand strategies
  • Develop significant relationships across all levels of the hospital's environment including decision makers and influencers.
Responsibilities
  • Serve as the commercial point of contact for designated hospitals and referring centres
  • Primary point of contact to support all customer needs
  • Ensure appropriate patient identification
  • Manage internal customer facing partners to ensure the customers have a positive experience with Gilead and our products
  • Navigate complex hospital environments and understand the needs/issues of various stakeholders at all levels within the account and find solutions to address these needs/issues
  • Collaborate and regularly communicate with colleagues in Quality, Pharmacovigilance, Marketing, and Customer Engagement
  • Engage with haematology Specialists to ensure appropriate patients are referred into Qualified Treatment centres
  • Maintain and continuously develop both disease state and product specific knowledge
  • Actively gain customer insights and provide timely follow-up on commitments and requests
  • Operate in compliance with all laws, regulations and policies that govern the conduct of activities
  • Develop significant business relationships with decision makers and key stakeholders within treatment centres
  • Support and Coordination of the qualification process of selected hospitals
  • Partner with marketing to oversee the execution of brand strategies, goals and promotional tactics aligned with customer facing efforts
  • Lead the development and execution of strategic account & commercial plans which will include clear goals and tactics aligned with corporate and commercial business objectives
  • Develop mechanisms and execute on processes to regularly monitor account activity against goals and provide on-going feedback to the marketing team
  • Manage a budget and use of budget/resources
  • Establish and maintain productive and collaborative working relationships with cross functional peers and teams across the Kite Pharma & Gilead organisation
  • Develop significant relationships with KOLs & the senior account level leadership as well as other decision makers
  • Provide support at professional meetings, including staffing exhibits, reporting on scientific sessions, Facilitate and provide timely feedback to appropriate Kite Pharma & Gilead management regarding account business trends, changes in the therapeutic landscape, industry issues and business opportunities.
Desired Qualifications
  • Scientific educational background preferred, or other related graduate-level degree is preferred

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and ensure sustainable practices. The company's goal is to enhance health equity and access to care, working with communities globally to remove barriers to healthcare and make its medicines available to those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery is revolutionizing the biopharmaceutical industry, benefiting companies like Gilead.
  • Gilead's lenacapavir development represents a significant advancement in HIV treatment.
  • Investor confidence in Gilead is strong, as shown by recent investments.

What critics are saying

  • Layoffs at Gilead may disrupt strategic decision-making and operational efficiency.
  • Competition from AI-driven drug discovery companies could outpace traditional methods.
  • STAT6 program partnership with LEO Pharma may face challenges in clinical success.

What makes Gilead Sciences unique

  • Gilead's lenacapavir offers a once-yearly HIV prevention, enhancing patient adherence.
  • Strategic partnership with LEO Pharma expands Gilead's inflammation research portfolio.
  • Gilead's manufacturing efficiencies provide a competitive edge in CAR-T cell therapy production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

SFist
Apr 2nd, 2025
April Fool's Day Around the Bay: Bob Lee's Family Has Sued His Convicted Killer Nima Momeni

Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.

Labiotech
Mar 27th, 2025
12 Ai Drug Discovery Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at 12 AI drug discovery companies. The COVID-19 pandemic revealed AI to be an essential tool in helping to find treatments and vaccines with greater speed and precision. Since then, there have been several drug discovery breakthroughs for AI within the biopharma industry, from helping to quickly and efficiently discover a new antibiotic called abaucin to combat a multi-drug resistant bacteria, to fully discovering and designing a drug that has entered clinical trials. Here are 12 AI drug discovery companies currently making great strides with their technology. Anima Biotech Technology: mRNA biology modulators Disease areas: Immunology, oncology and neuroscienceRecent news: Announced promising preclinical data for lead pulmonary fibrosis candidate Anima Biotech’s AI drug discovery technology is built around its mRNA Lightning.AI platform, which images hundreds of cellular pathways in both healthy and diseased cells to train disease-specific AI models, making use of neural networks to help these models distinguish between healthy and diseased cells and identify dysregulated pathways. These pathways are subsequently analyzed to uncover novel targets backed by experimental validation. Anima currently has 20 preclinical candidates being evaluated for immunology, oncology, and neuroscience indications, with its most advanced candidate indicated for the treatment of lung fibrosis. The company announced in February 2024 that this candidate had shown promising preclinical results and could open up new avenues for treating patients with idiopathic pulmonary fibrosis. The AI drug discovery company also has ongoing collaborations with several pharma giants. After initially partnering with Eli Lilly in 2018 and Takeda in 2021, its most recent partnership was formed with AbbVie in 2023 for the discovery and development of mRNA biology modulators against oncology and immunology targets. Atomwise Technology: TYK2 inhibitor  Disease area: Autoimmune and autoinflammatory diseasesRecent news: Published results showcasing AtomNet’s ability for drug discoveryAtomwise is leveraging the power of AI in an attempt to revolutionize small molecule drug discovery

Charities.org
Mar 25th, 2025
Sustainability News provided by 3BL

Gilead recently partnered with GRYT Health to host a New Lens on Lung Cancer workshop where people living with lung cancer and their loved ones shared their experience with stigma.

CSR Company
Mar 18th, 2025
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies

Gilead Sciences ranked in top five Most JUST list for biopharma companies.

Pipeline Review
Mar 12th, 2025
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

First clinical data for Gilead's investigational Once-Yearly Lenacapavir for HIV Prevention presented at CROI 2025 and published in The Lancet.